皮下注射替尔泊肽对比安慰剂或司美格鲁肽对成人2型糖尿病患者胰岛功能和胰岛素敏感性的影响:一项多中心、随机、双盲、平行组、1期临床试验
这项在德国两个中心进行的1期随机双盲平行组试验,将117例2型糖尿病患者按3:3:2随机分配至替尔泊肽15 mg、司美格鲁肽1 mg或安慰剂每周皮下注射,治疗28周。替尔泊肽较安慰剂显著改善钳夹处置指数(ETD 1.92 pmol m-2 L min-2 kg-1,95%CI 1.59-2.24,p<0.0001),且改善幅度显著大于司美格鲁肽(ETD 0.84,95%CI 0.46-1.21)。
要点
- 替尔泊肽15 mg每周一次治疗28周,钳夹处置指数较安慰剂显著升高(ETD 1.92,p<0.0001)。
- 替尔泊肽对钳夹处置指数的改善显著大于司美格鲁肽1 mg(ETD 0.84,95%CI 0.46-1.21)。
- 替尔泊肽较司美格鲁肽显著改善总胰岛素分泌率和胰岛素敏感性,两者安全性相似。
核心结论
- 替尔泊肽在2型糖尿病中的降糖疗效源于β细胞功能、胰岛素敏感性和胰高血糖素分泌等关键病理生理环节的同步改善,这些效应幅度大,有助于解释3期研究中观察到的显著降糖能力。
研究设计与样本
- 多中心、随机、双盲、平行组、1期临床试验,在德国两个中心进行,2019年6月28日至2021年4月8日筛查184人,入组117例20-74岁、2型糖尿病病程至少6个月、接受生活方式建议和稳定剂量二甲双胍(可联用一种其他稳定剂量口服降糖药)治疗的患者。
- 患者按3:3:2随机分配至替尔泊肽15 mg、司美格鲁肽1 mg或安慰剂每周皮下注射,终点测量在基线和治疗最后一周(第28周)进行。
- 主要终点为替尔泊肽对比安慰剂对钳夹处置指数从基线至第28周变化的影响,在药效学分析集中分析;安全性在安全性分析集中分析。
主要发现
- 替尔泊肽组钳夹处置指数从基线最小二乘均值0.3 pmol m-2 L min-2 kg-1(SE 0.03)升高1.9 pmol m-2 L min-2 kg-1(0.16),第28周总计2.3 pmol m-2 L min-2 kg-1(SE 0.16);安慰剂组从基线0.4 pmol m-2 L min-2 kg-1(SE 0.04)变化0.0 pmol m-2 L min-2 kg-1(0.03),第28周0.3(SE 0.03);替尔泊肽对比安慰剂的估计治疗差异(ETD)为1.92(95%CI 1.59-2.24),p<0.0001。
- 替尔泊肽对钳夹处置指数的改善显著大于司美格鲁肽(ETD 0.84 pmol m-2 L min-2 kg-1,95%CI 0.46-1.21),反映在总胰岛素分泌率(ETD 102.09 pmol min-1 m-2,95%CI 51.84-152.33)和胰岛素敏感性(ETD 1.52 mg min-1 kg-1,95%CI 0.53-2.52)均显著优于司美格鲁肽。
- 在餐耐量试验中,替尔泊肽较安慰剂显著减少血糖波动(胰岛素和胰高血糖素浓度更低),且对这些变量的影响大于司美格鲁肽。
- 替尔泊肽与司美格鲁肽安全性特征相似,胃肠道不良事件最常见:恶心分别为替尔泊肽11例(24%)、司美格鲁肽13例(30%)、安慰剂7例(25%);腹泻分别为9例(20%)、13例(30%)、6例(21%);呕吐分别为3例(7%)、5例(11%)、1例(4%)。无死亡。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, shows a remarkable ability to lower blood glucose, enabling many patients with long-standing type 2 diabetes to achieve normoglycaemia. We aimed to understand the physiological mechanisms underlying the action of tirzepatide in type 2 diabetes. METHODS: This multicentre, randomised, double-blind, parallel-arm, phase 1 study was done at two centres in Germany. Eligible patients were aged 20-74 years, had type 2 diabetes for at least 6 months, and were being treated with lifestyle advice and stable doses of metformin, with or without one additional stable dose of another oral antihyperglycaemic medicine, 3 months before study entry. Via a randomisation table, patients were randomly assigned (3:3:2) to subcutaneously receive either tirzepatide 15 mg, semaglutide 1 mg, or placebo once per week. Endpoint measurements were done at baseline and the last week of therapy (week 28). The primary endpoint was the effect of tirzepatide versus placebo on the change in clamp disposition index (combining measures of insulin secretion and sensitivity) from baseline to week 28 of treatment and was analysed in the pharmacodynamic analysis set, which comprised all randomly assigned participants who received at least one dose of a study drug and had evaluable pharmacodynamic data. Safety was analysed in the safety population, which comprised all randomly assigned participants who received at least one dose of a study drug. Secondary endpoints included the effect of tirzepatide versus semaglutide on the change in clamp disposition index from baseline to week 28 of treatment, glucose control, total insulin secretion rate, M value (insulin sensitivity), and fasting and postprandial glucagon concentrations. Exploratory endpoints included the change in fasting and postprandial insulin concentrations. This study is registered with ClinicalTrials.gov, NCT03951753, and is complete. FINDINGS: Between June 28, 2019, and April 8, 2021, we screened 184 individuals and enrolled 117 participants, all of whom were included in the safety population (45 in the tirzepatide 15 mg group, 44 in the semaglutide 1 mg group, and 28 in the placebo group). Because of discontinuations and exclusions due to missing or unevaluable data, 39 patients in each treatment group and 24 patients in the placebo group comprised the pharmacodynamic analysis set. With tirzepatide, the clamp disposition index increased from a least squares mean of 0·3 pmol m-2 L min-2 kg-1 (SE 0·03) at baseline by 1·9 pmol m-2 L min-2 kg-1 (0·16) to total 2·3 pmol m-2 L min-2 kg-1 (SE 0·16) at week 28 and, with placebo, the clamp disposition index did not change much from baseline (least squares mean at baseline 0·4 pmol m-2 L min-2 kg-1 [SE 0·04]; change from baseline 0·0 pmol m-2 L min-2 kg-1 [0·03]; least squares mean at week 28 0·3 [SE 0·03]; estimated treatment difference [ETD] tirzepatide vs placebo 1·92 [95% CI 1·59-2·24]; p<0·0001). The improvement with tirzepatide in clamp disposition index was significantly greater than with semaglutide (ETD 0·84 pmol m-2 L min-2 kg-1 [95% CI 0·46-1·21]). This result reflected significant improvements in total insulin secretion rate (ETD 102·09 pmol min-1 m-2 [51·84-152·33]) and insulin sensitivity (ETD 1·52 mg min-1 kg-1 [0·53-2·52]) for tirzepatide versus semaglutide. On meal tolerance testing, tirzepatide significantly reduced glucose excursions (lower insulin and glucagon concentrations) compared with placebo, with effects on these variables being greater than with semaglutide. The safety profiles of tirzepatide and semaglutide were similar, with gastrointestinal adverse events being the most common (11 [24%], 13 [30%], and seven [25%] with nausea; nine [20%], 13 [30%], and six [21%] with diarrhoea; and three [7%], five [11%], and one [4%] with vomiting, for tirzepatide, semaglutide, and placebo, respectively). There were no deaths. INTERPRETATION: The glycaemic efficacy of GIP/GLP-1 receptor agonist tirzepatide in type 2 diabetes results from concurrent improvements in key components of diabetes pathophysiology, namely β-cell function, insulin sensitivity, and glucagon secretion. These effects were large and help to explain the remarkable glucose-lowering ability of tirzepatide seen in phase 3 studies. FUNDING: Eli Lilly.
引用
- Heise T, Mari A, DeVries JH, et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol. 2022. PMID: 35468322. doi:10.1016/S2213-8587(22)00085-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。